Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
ovarian cancer
Biotech
IMV drops 3rd of staff in refocus on lead oncology asset
A strategic reorganization will see the biotech focus on its lead, oncology asset MVP-S at the expense of a third of his workforce.
James Waldron
Sep 15, 2022 9:45am
ESMO: Data boosts Regeneron's plans to 'take on' ovarian cancer
Sep 12, 2022 10:10am
VBL lays off 35% of staff after failure-induced stock shock
Aug 2, 2022 11:03am
Panic infects VBL investors as therapy fails phase 3 cancer test
Jul 20, 2022 6:30am
Roche pays Repare $125M to join Big Pharma peers in cancer race
Jun 2, 2022 8:27am
Investors fork out $76M for piece of Pheast's cancer therapies
Apr 26, 2022 11:00am
